| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11892-009-0015-8 |
| P698 | PubMed publication ID | 19192430 |
| P2093 | author name string | Stuart W Zarich | |
| P2860 | cites work | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association | Q22241916 |
| Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review | Q22242077 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. | Q50535464 | ||
| A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. | Q51472824 | ||
| The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. | Q51529673 | ||
| Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans | Q51584502 | ||
| Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. | Q53359026 | ||
| Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs | Q57300672 | ||
| Successful Cardiopulmonary Resuscitation After Cardiac Arrest as a “Sepsis-Like” Syndrome | Q58419479 | ||
| Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. | Q64998688 | ||
| Barriers to regimen adherence among persons with insulin-dependent diabetes | Q68873513 | ||
| Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited | Q73542916 | ||
| [Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43] | Q79967063 | ||
| PROactive study | Q94467284 | ||
| Nonhypoglycemic effects of thiazolidinediones | Q31973270 | ||
| Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment | Q34000840 | ||
| The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients | Q34329426 | ||
| Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol | Q34434723 | ||
| Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial | Q34571157 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death | Q34659938 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus | Q35894298 | ||
| The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium | Q35961954 | ||
| Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis | Q35961992 | ||
| George Lyman Duff Memorial Lecture. Atherogenesis in diabetes | Q36136751 | ||
| Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
| Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials | Q36955489 | ||
| PROactive: time for a critical appraisal | Q37122745 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Insulin infusion in acute illness | Q42928076 | ||
| Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled tr | Q43520539 | ||
| Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 | ||
| Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide | Q43653267 | ||
| Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. | Q43711367 | ||
| In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone | Q43803587 | ||
| Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus | Q44193427 | ||
| Diabetic macrovascular disease: the glucose paradox? | Q44228460 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 | ||
| Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study | Q44532772 | ||
| Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus | Q44786820 | ||
| The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. | Q45092166 | ||
| Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. | Q45124478 | ||
| Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study | Q45256257 | ||
| Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study | Q46481435 | ||
| A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
| Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project | Q46570727 | ||
| Improved clinical outcomes associated with metformin in patients with diabetes and heart failure | Q46722279 | ||
| Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
| The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. | Q46835037 | ||
| Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart | Q46835041 | ||
| Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). | Q46848592 | ||
| The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits | Q46871340 | ||
| Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) | Q47248997 | ||
| P433 | issue | 1 | |
| P921 | main subject | glucose | Q37525 |
| P304 | page(s) | 87-94 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Potential of glucose-lowering drugs to reduce cardiovascular events | |
| P478 | volume | 9 |
Search more.